DEFB129

Across TCGA pan-cancer cohorts, DEFB129 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated DEFB129 data layer compared with 1 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher DEFB129 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEFB129 expression acts as an unfavorable survival marker, although some lineages such as KICH show a favorable association.

THCA, BLCA, and SCLC are the cancer types where DEFB129 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Tertile	III,IV	0.158	0.662	.006	66	view →
BLCA	OS	Tertile	IV	0.051	0.600	<.001	36	view →
SCLC	OS	Tertile	All	0.055	0.653	<.001	27	view →
KICH	OS	Median	All	0.971	0.750	.007	21	view →
DLBC	OS	Tertile	All	0.219	0.900	.043	6	view →
LGG	DFS	Tertile	All	0.597	0.851	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DEFB129–THCA (DFS)

Open the THCA breakdown →